Healthy CD4(+) T lymphocytes are not affected by targeted therapies against the PI3K/Akt/mTOR pathway in T-cell acute lymphoblastic leukemia

An attractive molecular target for novel anti-cancer therapies is the phosphatidylinositol 3-kinase (PI3K)/Akt/mammalian target of rapamycin (mTOR) pathway which is commonly deregulated in many types of cancer. Nevertheless, the effects of PI3K/Akt/mTOR inhibitors on T lymphocytes, a key component o...

Descripción completa

Detalles Bibliográficos
Autores principales: Alameen, Ayman A.M., Simioni, Carolina, Martelli, Alberto M., Zauli, Giorgio, Ultimo, Simona, McCubrey, James A., Gonelli, Arianna, Marisi, Giorgia, Ulivi, Paola, Capitani, Silvano, Neri, Luca M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2016
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5342446/
https://www.ncbi.nlm.nih.gov/pubmed/27494886
http://dx.doi.org/10.18632/oncotarget.10984

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5342446/
https://www.ncbi.nlm.nih.gov/pubmed/27494886
http://dx.doi.org/10.18632/oncotarget.10984

Ejemplares similares